Up to 200 million people worldwide may be living with undiagnosed mild cognitive impairment – many unaware that early intervention could change their trajectory. In this episode, host Alex Maiersperger is joined by Marc Jones, CEO of Altoida, and Dr. Mona Flores of Altoida's Clinical Advisory Board to explore how AI and digital biomarkers are reshaping early detection of cognitive decline. Digital biomarkers register how the brain processes information, translating how brain networks function through the way we move, speak and remember. Altoida's platform tracks motor skills, speech complexity and memory recall, mapping them to data points to identify where brain function diverges from that of a healthy population. They also discuss how AI acts as a force multiplier, giving clinicians tools to spot trends, make informed decisions and spend more time with patients.